Private oncology outfit Oncternal uses GTx as shell to make Nasdaq debut

San Diego Biotechnology Network
San Diego Biotechnology Network
Private oncology outfit Oncternal uses GTx as shell to make Nasdaq debut
Loading
/

Months after declaring it was exploring strategic options following the failure of its lead experimental drug in a mid-stage study involving patients with stress urinary incontinence, GTx has agreed to be the vehicle that private oncology-focused biotech Oncternal Therapeutics is using to leap onto the Nasdaq.

James Breitmeyer

The new firm ? to be called Oncternal Therapeutics ? will trade under the symbol $ONCT, and Oncternal shareholders will hold three-fourths (75%) of the San Diego, Califor